Merck KGaA, Janssen to Develop Automated Diagnostic Tool for Neglected Tropical Diseases
02 July 2020 - 8:00PM
Dow Jones News
By Giulia Petroni
Merck KGaA said Thursday that it would partner with Janssen
Pharmaceutica NV to develop an artificial intelligence-based
diagnostic tool for the detection of neglected tropical
diseases.
The German pharmaceutical and chemicals company said the
prototype that is being tested consists of an automated microscope
with AI and data visualisation tool. It enables the counting of
parasite eggs that develop into parasitic worms of either
schistosomiasis or soil-transmitted helminthiasis.
"This automated counting process is aimed at being both faster
and more reliable than the current survey method, in which a lab
technician counts the eggs in each sample manually," it said.
The prototype testing is set to continue throughout the year and
pass to the clinical utility testing phase in 2021 through 2023,
according to Merck KGaA.
Janssen Pharmaceutica is part of the Janssen Pharmaceutical
Companies of Johnson & Johnson.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
July 02, 2020 05:45 ET (09:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to May 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2023 to May 2024